A Host-Protein Test for Differentiating Bacterial From Viral Infection: Diagnostic Accuracy in Elderly Patients
Abstract
Objectives: Older adults are vulnerable to infection and are difficult to diagnose. This study assessed the performance of MeMed BV (MMBV), a host-protein test for differentiating bacterial from viral infection, in adults ≥65 years.
Methods: Post hoc pooled and meta-analysis of adults with suspected acute infections enrolled in 3 prospective studies. MMBV results were interpreted as bacterial/viral/equivocal per manufacturer's instructions. Reference standard infection etiology was adjudicated by experienced physicians who were blinded to MMBV. Diagnostic accuracy for bacterial infection was calculated for MMBV results (area under the receiver operating characteristic curve [AUC], bin analysis) and for unequivocal MMBV results (sensitivity/specificity). MMBV's potential impact on antibiotic use was estimated by comparing MMBV-guided decisions to actual practice.
Results: A total of 754 younger (18-64 years) and 248 older (≥65 years) adults were included. Among older adults, the median age was 75.0 years (IQR, 69.0, 82.0), 53.2% were male, 68.1% were hospitalized, and 79.0% had ≥3 comorbidities. Respiratory tract infections were common (76.2%), and 85.1% were prescribed antibiotics. A total of 111 patients were assigned a bacterial reference standard infection etiology, 77 a viral etiology, and 60 an indeterminate etiology. In pooled analysis, MMBV attained comparable AUC in older (0.95; 95% CI, 0.92-0.98) vs younger adults (0.95; 0.93-0.97). Focusing on older adults, 96.2%…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.